Core Viewpoint - The medical services sector experienced a decline of 1.5% on January 20, with Meidisi leading the drop. The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1]. Group 1: Stock Performance - The top gainers in the medical services sector included *ST Shengwu, which rose by 4.82% to close at 9.36, and Wo Men Fei Yu, which increased by 3.73% to 39.18 [1]. - Meidisi led the decliners, falling by 5.01% to a closing price of 63.18, followed by Bidai Pharmaceutical, which dropped 4.19% to 66.59 [2]. - The overall trading volume in the medical services sector showed significant activity, with Meidisi recording a transaction amount of 375 million [2]. Group 2: Capital Flow - The medical services sector saw a net outflow of 1.068 billion from institutional investors, while retail investors contributed a net inflow of 903 million [2]. - Notable stocks with significant capital inflow included Meidian Health, which had a net inflow of 40.6557 million from retail investors, despite a net outflow from institutional investors [3]. - The capital flow data indicates a mixed sentiment among different investor types, with institutional investors withdrawing funds while retail investors increased their positions [2][3].

Group 1 - The core viewpoint of the news is that Medisi's stock has experienced fluctuations, with a recent decline of 2.01% and a total market value of 8.756 billion yuan [1] - As of January 20, Medisi's stock price is 65.17 yuan per share, with a trading volume of 69.0561 million yuan and a turnover rate of 0.78% [1] - The company has seen a year-to-date stock price increase of 15.55%, but a decline of 9.61% over the last five trading days [1] Group 2 - Medisi's main business involves providing comprehensive new drug research and development services to pharmaceutical companies and other new drug research institutions, with preclinical research accounting for 50.34% and drug discovery and pharmaceutical research for 49.64% of its revenue [1] - As of September 30, the number of Medisi's shareholders has increased by 27.83% to 16,500, while the average circulating shares per person have decreased by 21.96% to 8,149 shares [2] - For the period from January to September 2025, Medisi achieved operating revenue of 843 million yuan, representing a year-on-year growth of 5.14%, while the net profit attributable to the parent company was -29.6849 million yuan, showing a year-on-year increase of 76.93% [2] Group 3 - Medisi has distributed a total of 158 million yuan in dividends since its A-share listing, with cumulative distributions of 33.9365 million yuan over the past three years [3]

2026年1月11日，ACCESS ASIA BD Forum @JPM2026在美国旧金山洲际酒店圆满落幕。本次论坛汇聚 了来自全球数十家跨国药企、生物科技公司及研发服务组织的决策者与科学家，共同围绕亚洲尤其是中 国在全球生物医药创新与交易中的战略角色展开深度对话。作为特邀赞助方及演讲嘉宾，美迪西在本次 论坛中全方位展示了其作为药物研发一体化合作伙伴的赋能能力，并与全球行业领袖共议合作前景。 会议上，美迪西药物发现及药学研究事业部总裁段茂圣博士进行题为《中国CRO驱动下的创新生态如 何孵化资产并推动全球交易》的主题演讲，他指出，中国CRO行业已逐步实现从"服务提供者"到"创新 生态共建者"的战略转型。依托覆盖药物发现、药学研究及临床前研究的全链条一站式研发服务平台， 美迪西持续推动国内外创新药项目的高效进展，显著缩短研发周期，并为全球许可引进(license-in)与对 外授权(license-out)提供关键技术支持。段博士结合多项合作案例进一步阐明，中国CRO已在复杂靶点 验证、差异化分子设计及中美双报策略等方面发挥着日益重要的行业推动作用。 此外，美迪西美国公司总裁林庆聪博士主持了题为《从交易到全球舞 ...

【环球网财经综合报道】"中国CRO行业已逐步实现从'服务提供者'到'创新生态共建者'的战略转型。"近日，在旧金山 洲际酒店举办的ACCESS ASIA药通亚洲BD论坛上，美迪西药物发现及药学研究事业部总裁段茂圣博士作出上述发 言。 作为摩根大通医疗健康年会（JP Morgan Healthcare Conference）期间最具影响力的亚洲专题盛会，论坛议题涵盖抗体 偶联药物（ADC）、细胞与基因治疗（CGT）以及人工智能（AI）驱动的药物发现等前沿领域，反映了当前全球资本 创新源的兴趣所在。 随着中国药监政策与国际接轨、人才回流与技术积累加速，中国在全球医药创新版图中的角色日益重要。在此背景 下，中国领先的一站式药物研发服务平台美迪西（688202.SH），作为本届论坛的特邀赞助方与核心演讲嘉宾亮相国 际舞台，段茂圣在会上系统阐述了中国创新药研发体系的最新进展，并结合多项合作案例进一步说明，中国CRO在复 杂靶点验证、差异化分子设计及中美双报策略等关键领域，正发挥着愈发重要的行业推动作用，充分展示了其作为连 接"东方研发"与"全球市场"桥梁的作用。 公开资料显示，作为全球领先的一站式临床前综合研发服务CRO ...

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

Core Concept - The article discusses the transformative potential of AI for Science (AI4S) in reshaping China's technological landscape, emphasizing its role in enhancing foundational research efficiency and addressing critical industry challenges [3][9][10]. Group 1: AI4S Overview - AI4S represents a paradigm shift in scientific research, moving from a trial-and-error approach to a data and model-driven methodology, which is crucial for overcoming efficiency bottlenecks in foundational research [3][4]. - The integration of AI into foundational research is seen as a key factor for China's technological breakthroughs, particularly in critical sectors such as new materials, biomedicine, and semiconductors [3][9]. Group 2: Applications in New Materials - Fangda Carbon (600516.SH) and Jingtai Technology's collaboration exemplifies the application of AI4S in new materials, significantly reducing the research and development cycle from 2-3 years to 3-6 months [5]. - The partnership aims to optimize production processes and improve product yield by over 15%, showcasing the practical benefits of AI integration in traditional manufacturing [5]. Group 3: Applications in Biomedicine - Medicy (688202.SH) has redefined the drug development process through AI, achieving a significant reduction in the clinical research cycle by 40% and enhancing the accuracy of toxicity predictions to 92% [6][7]. - The company’s AI-driven platform integrates advanced technologies like Google’s AlphaFold3 and NVIDIA’s BioNeMo, allowing for rapid iteration in drug discovery and positioning China at the forefront of global pharmaceutical research [6][7]. Group 4: Applications in Semiconductors - DaoTech (300409.SZ) addresses the computational challenges in AI4S by developing specialized chips for atomic-level scientific calculations, which are essential for both materials and chip research [8]. - The establishment of the Hexi Atomic Computing Center enables a synergistic relationship between chip development and materials design, enhancing the efficiency of both fields [8]. Group 5: Market Dynamics and Future Outlook - The success of AI4S in China is attributed to a combination of industry demand, technological innovation, and supportive government policies, which collectively foster a conducive environment for AI integration in foundational research [9]. - Despite challenges such as data scarcity and talent shortages, AI4S presents unprecedented opportunities for China to advance in foundational research areas, potentially leading to a shift from a follower to a leader in global technology innovation [9][10].

Group 1 - The innovative drug concept stocks opened strong, with Hongbo Pharmaceutical hitting the daily limit up of 20% [1] - Chengdu Xian Dao and Ruizhi Pharmaceutical both rose over 10% [1] - Yaoshi Technology, Boji Pharmaceutical, Meidixi, and Haoyuan Pharmaceutical all increased by more than 5% [1]

Group 1 - The core viewpoint of the news is that Meidi Xi's stock price increased by 5%, reaching 71.16 CNY per share, with a trading volume of 369 million CNY and a turnover rate of 4.00%, resulting in a total market capitalization of 9.561 billion CNY [1] - Meidi Xi is a biopharmaceutical company based in Shanghai, established on February 2, 2004, and listed on November 5, 2019, primarily providing comprehensive new drug research and development services for pharmaceutical companies and other new drug research institutions [1] - The company's main business revenue composition includes preclinical research at 50.34%, drug discovery and pharmaceutical research at 49.64%, and other (supplementary) at 0.01% [1] Group 2 - From the perspective of fund holdings, one fund under Wan Jia Fund has a significant position in Meidi Xi, with the Wan Jia Guo Zheng 2000 ETF holding 99,500 shares, accounting for 0.54% of the fund's net value, making it the second-largest holding [2] - The Wan Jia Guo Zheng 2000 ETF was established on June 29, 2022, with a current scale of 1.286 billion CNY, and has achieved a return of 4.84% this year, ranking 1511 out of 5509 in its category [2] - The fund manager, Yang Kun, has a tenure of 6 years and 80 days, with the fund's total asset scale at 13.868 billion CNY, achieving the best return of 81.38% and the worst return of -32.3% during his tenure [2]

Group 1 - The core viewpoint of the news highlights the performance and growth of the Tianhong Innovation Drug ETF (517380), which has seen significant trading activity and net inflows, indicating strong investor interest in the innovative pharmaceutical sector [1] - As of January 8, the Tianhong Innovation Drug ETF reached a new high with a total scale of 1.597 billion yuan and 1.980 billion shares outstanding, reflecting robust market demand [1] - The ETF tracks the Hang Seng Shanghai-Shenzhen Hong Kong Innovation Drug Select 50 Index (HSSSHID), which includes a diverse selection of 50 leading innovative pharmaceutical companies, with a composition of 40% Hong Kong stocks and 60% A-shares [1] Group 2 - Notable achievements in the innovative pharmaceutical sector include Shiyao Group's R&D expenses of 4.185 billion yuan for the first three quarters of 2025, focusing on ADC, GLP-1, and small nucleic acid pipelines, with total authorized amounts exceeding 9.7 billion USD [2] - BeiGene is projected to achieve a profit of 200 million USD in 2025, with expectations of reaching 600-800 million USD in 2026, as several solid tumor drugs enter critical clinical stages [2] - Three Life Sciences has partnered with Pfizer for a 6 billion USD dual antibody licensing deal, receiving an upfront payment of 1.4 billion USD, with 20 clinical studies planned for 2026 [2]

广发证券股份有限公司 关于上海美迪西生物医药股份有限公司 2025 年度持续督导现场检查报告 根据《上海证券交易所科创板股票上市规则》等有关法律、法规的规定，广 发证券股份有限公司（以下简称"广发证券"、"保荐机构"）作为正在履行上海 美迪西生物医药股份有限公司（以下简称"美迪西"、"上市公司"、"公司"）持 续督导工作的保荐机构，对公司 2025 年 1 月 1 日至本次现场检查期间（以下简 称"本持续督导期间"）的运行情况进行了现场检查，现就现场检查的有关情况 报告如下： 一、本次现场检查的基本情况 （二）保荐代表人 黄晟、易志强 （三）现场检查时间 2025 年 12 月 29 日 （四）现场检查人员 易志强 公司治理和内部控制情况、信息披露情况、公司的独立性以及与控股股东、 实际控制人及其他关联方资金往来情况、募集资金使用情况、关联交易、对外担 保、重大对外投资、公司经营情况等。 （六）现场检查程序 （一）保荐机构 广发证券股份有限公司 （五）现场检查内容 查看上市公司主要生产经营场所并与上市公司相关人员进行访谈；查阅公司 在本持续督导期间召开的历次董事会、股东会等会议资料；查阅公司建立的有关 内控制 ...